Redox mechanism of anticancer drug idarubicin and in-situ evaluation of interaction with DNA using an electrochemical biosensor

Kara, Hayriye Eda Şatana

doi:10.1016/j.bioelechem.2014.06.002

Cited by 51 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…Detection of anticancer drugs with electrochemical biosensors is mainly based on the monitoring of intrinsic redox activity of DNA molecules immobilized on the electrode interface [7,8,9]. Thus, idarubicin was detected in the micromolar range of its concentrations by monitoring guanine oxidation at 1.1 V with cyclic voltammetry (CV) and differential pulse voltammetry (DPV) [8]. DNA immobilized onto reduced graphene oxide decorated with Au nanoparticles has been employed for quantification of interaction with doxorubicin by DPV technique using oxidation peak current promoted by the drug binding (limit of detection (LOD) 8 μg/mL) [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Electrochemical DNA Sensors with Layered Polyaniline—DNA Coating for Detection of Specific DNA Interactions

Kulikova

Porfireva

Evtugyn

et al. 2019

Sensors

View full text Add to dashboard Cite

A DNA sensor has been proposed on the platform of glassy carbon electrode modified with native DNA implemented between two electropolymerized layers of polyaniline. The surface layer was assembled by consecutive stages of potentiodynamic electrolysis, DNA drop casting, and second electrolysis, which was required for capsulation of the DNA molecules and prevented their leaching into the solution. Surface layer assembling was controlled by cyclic voltammetry, electrochemical impedance spectroscopy, atomic force, and scanning electron microscopy. For doxorubicin measurement, the DNA sensor was first incubated in the Methylene blue solution that amplified signal due to DNA intercalation and competition with the doxorubicin molecules for the DNA binding sites. The charge transfer resistance of the inner layer interface decreased with the doxorubicin concentration in the range from 1.0 pM to 0.1 μM (LOD 0.6 pM). The DNA sensor was tested for the analysis of spiked artificial urine samples and showed satisfactory recovery in concentration range of 0.05–10 μM. The DNA sensor developed can find application in testing of antitumor drugs and some other DNA damaging factors.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Electrochemical DNA Sensors with Layered Polyaniline—DNA Coating for Detection of Specific DNA Interactions

Kulikova

Porfireva

Evtugyn

et al. 2019

Sensors

View full text Add to dashboard Cite

show abstract

“…Idarubicin is a semisynthetic analog of the antineoplastic anthracycline antibiotic daunorubicin, and is used for different types of leukemia. Idarubicin is irreversibly oxidized at a GCE, in a pH-dependent, one-electron and one-proton transfer process [86].…”

Section: Antibioticsmentioning

confidence: 99%

“…The idarubicin-dsDNA interaction was studied in incubated solutions and at multilayer dsDNA, poly(A), and poly(G) electrochemical biosensors [86]. The idarubicin intercalation into the dsDNA double helix was demonstrated via the decrease in G r and A r oxidation peak currents when increasing the incubation time, but no oxidative DNA damage related to the appearance of the 8-oxoG and 2,8-DHA oxidation peaks was observed.…”

Section: Antibioticsmentioning

confidence: 99%

DNA Electrochemical Biosensors for In Situ Probing of Pharmaceutical Drug Oxidative DNA Damage

Chiorcea-Paquim

Oliveira-Brett

2021

Sensors

View full text Add to dashboard Cite

Deoxyribonucleic acid (DNA) electrochemical biosensors are devices that incorporate immobilized DNA as a molecular recognition element on the electrode surface, and enable probing in situ the oxidative DNA damage. A wide range of DNA electrochemical biosensor analytical and biotechnological applications in pharmacology are foreseen, due to their ability to determine in situ and in real-time the DNA interaction mechanisms with pharmaceutical drugs, as well as with their degradation products, redox reaction products, and metabolites, and due to their capacity to achieve quantitative electroanalytical evaluation of the drugs, with high sensitivity, short time of analysis, and low cost. This review presents the design and applications of label-free DNA electrochemical biosensors that use DNA direct electrochemical oxidation to detect oxidative DNA damage. The DNA electrochemical biosensor development, from the viewpoint of electrochemical and atomic force microscopy (AFM) characterization, and the bottom-up immobilization of DNA nanostructures at the electrode surface, are described. Applications of DNA electrochemical biosensors that enable the label-free detection of DNA interactions with pharmaceutical compounds, such as acridine derivatives, alkaloids, alkylating agents, alkylphosphocholines, antibiotics, antimetabolites, kinase inhibitors, immunomodulatory agents, metal complexes, nucleoside analogs, and phenolic compounds, which can be used in drug analysis and drug discovery, and may lead to future screening systems, are reviewed.

show abstract

“…Today, DNA is strategically set as a target for ligands in treating many human diseases especially for cancer therapeutics [ 5 , 6 ]. Therefore, in-depth understanding of protein-DNA and drug-DNA binding interactions is the key to understand disease mechanisms which helps in the drug design in order to successfully tackle a range of diseases [ [7] , [8] , [9] ].…”

Section: Introductionmentioning

confidence: 99%

Recent development of nucleic acid nanosensors to detect sequence-specific binding interactions: From metal ions, small molecules to proteins and pathogens

Zheng

Tan

2020

Sensors International

View full text Add to dashboard Cite

DNA carries important genetic instructions and plays vital roles in regulating biological activities in living cells. Proteins such as transcription factors binds to DNA to regulate the biological functions of DNA, and similarly many drug molecules also bind to DNA to modulate its functions. Due to the importance of protein-DNA and drug-DNA binding, there has been intense effort in developing novel nanosensors in the same length scale as DNA, to effectively study these binding interactions in details. In addition, aptamers can be artificially selected to detect metal ions and pathogens such as bacteria and viruses, making nucleic acid nanosensors more versatile in detecting a large variety of analytes. In this minireview, we first explained the different types and binding modes of protein-DNA and drug-DNA interactions in the biological systems, as well as aptamer-target binding. This was followed by the review of five types of nucleic acid nanosensors based on optical or electrochemical detection. The five types of nucleic acid nanosensors utilizing colorimetric, dynamic light scattering (DLS), surface-enhanced Raman spectroscopy (SERS), fluorescence and electrochemical detections have been recently developed to tackle some of the challenges in high-throughput screening technology for large scale analysis, which is especially useful for drug development and mass screening for pandemic outbreak such as SARS or COVID-19.

show abstract

Redox mechanism of anticancer drug idarubicin and in-situ evaluation of interaction with DNA using an electrochemical biosensor

Cited by 51 publications

References 23 publications

Electrochemical DNA Sensors with Layered Polyaniline—DNA Coating for Detection of Specific DNA Interactions

Electrochemical DNA Sensors with Layered Polyaniline—DNA Coating for Detection of Specific DNA Interactions

DNA Electrochemical Biosensors for In Situ Probing of Pharmaceutical Drug Oxidative DNA Damage

Recent development of nucleic acid nanosensors to detect sequence-specific binding interactions: From metal ions, small molecules to proteins and pathogens

Contact Info

Product

Resources

About